Print PDF News

David Gindler Named Managing Partner of Irell & Manella


Irell & Manella LLP has elected David Gindler as its next managing partner, effective January 1, 2019. Gindler has long been in firm management, having served on Irell’s executive committee for six years. He will continue to practice full-time as a member of the firm’s litigation and intellectual property practice groups.

“It is truly a privilege to be entrusted by my partners to lead one of the country’s most respected law firms,” said Gindler, who will succeed the firm’s current managing partner, Ellisen Turner. “Under Ellisen’s leadership, we have had an extraordinarily successful year—in fact, the most profitable year in the firm’s history—and are well-positioned heading into 2019. Irell has a longstanding culture of excellence, both in terms of the results we deliver for our clients and the collaborative environment that fosters our creativity and innovation. I look forward to working with Ellisen to continue building on our successes.”

“David is a brilliant lawyer who is deeply devoted to his clients, his colleagues and our wider community, and I couldn’t be more confident about our future with him at the helm,” said Turner. “I am truly proud of what we have been able to accomplish during my time as managing partner, and particularly the new partner elevations that we are soon to announce. Although my professional and personal plans prevent me from continuing to serve in the role at this time, I know that as managing partner David will continue to realize our shared vision—one firm, one family, committed to excellence.”

While nationally recognized for his work in life sciences, Gindler’s work spans a broad array of industries and technologies. He has achieved extraordinary trial outcomes for both plaintiffs and defendants, including a $302 million verdict for breach of a research and license agreement, and defeating a $217 million damages claim where liability had already been established in an earlier trial handled by a different law firm. Most recently, Gindler has been representing Genentech and Biogen in high-stakes litigation against multiple companies seeking to market a “biosimilar” version of the blockbuster drug, Rituxan. His numerous honors and awards include being recognized in Chambers USA in the areas of intellectual property, patent and life sciences law, being named as one of California's "Top IP Litigators" by the Daily Journal, and being honored by LMG Life Sciences Awards as "California General Patent Litigator of the Year" (2017) and with the "Patent Impact Case of the Year Award" (2016) for his work on Ariosa Diagnostics v. Sequenom.

Outside of the firm, Gindler is an active supporter of the nonprofit performing arts community. He currently serves as chair of the Antaeus Theatre Company Board of Directors. He also serves on the boards of the Los Angeles Philharmonic, the Los Angeles Master Chorale and Beth Morrison Projects. Gindler earned his J.D. at UCLA School of Law and his B.A from Pomona College.


Jump to Page